1h Free Analyst Time
The publisher has been monitoring the type 1 diabetes drugs market and it is poised to grow by $2.83 billion during 2021-2025, progressing at a CAGR of almost 6% during the forecast period. The report on the type 1 diabetes drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the growing prevalence of type 1 diabetes and feasibility of early diagnosis of type 1 diabetes.
The type 1 diabetes drugs market analysis includes the product segment and geographic landscape.
The type 1 diabetes drugs market is segmented as below:
By Product
- Long-acting insulins
- Rapid-acting insulins
- Pre-mixed insulins
- Non-insulin drugs
By Geography
- North America
- Europe
- Asia
- ROW
This study identifies the expected launch of novel products as one of the prime reasons driving the type 1 diabetes drugs market growth during the next few years.
The report on type 1 diabetes drugs market covers the following areas:
- Type 1 diabetes drugs market sizing
- Type 1 diabetes drugs market forecast
- Type 1 diabetes drugs market industry analysis
The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading type 1 diabetes drugs market vendors that include Astellas Pharma Inc., AstraZeneca Plc, Biocon Ltd., Bristol-Myers Squibb Co., Eli Lilly and Co., MannKind Corp., Novo Nordisk AS, Actiza Pharmaceutical Pvt. Ltd., Sanofi SA, and Viatris Inc. Also, the type 1 diabetes drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
Executive Summary
Market Landscape
Market Sizing
Five Forces Analysis
Market Segmentation by Product
Geographic Landscape
Vendor Landscape
Vendor Analysis
Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global type 1 diabetes drugs market: Astellas Pharma Inc., AstraZeneca Plc, Biocon Ltd., Bristol-Myers Squibb Co., Eli Lilly and Co., MannKind Corp., Novo Nordisk AS, Actiza Pharmaceutical Pvt. Ltd., Sanofi SA, and Viatris Inc.Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is the expected launch of novel products.'
According to the report, one of the major drivers for this market is the growing prevalence of type 1 diabetes.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Astellas Pharma Inc.
- AstraZeneca Plc
- Biocon Ltd.
- Bristol-Myers Squibb Co.
- Eli Lilly and Co.
- MannKind Corp.
- Novo Nordisk AS
- Actiza Pharmaceutical Pvt. Ltd.
- Sanofi SA
- Viatris Inc.